The boom of pharmaceutical companies, which had benefited from COVID-19, has subsided since the third quarter. Representatively, Roche Group suffered a sharp drop in sales of diagnostic kits and treatments in the third quarter. Roche Group supplies Actemra and Ronapreve, a treatment for COVID-19, and Roche Diagnostics manufactures a COVID-19 diagnostic kit. In the third quarter of this year, Actemra fell 42% year-on-year. Ronapreve's sales also shrank by 36%. Sales of Roche Diagnostics' COVID-19 diagnostic kit, which introduced the first COVID-19 diagnostic kit at the time of the outbreak of COVID-19, also fell sharply. Roche believes that it is no longer possible to benefit from COVID-19 from the third quarter. Roche